|
LY-2623091
|
DB15367 |
[LY-2623091 is under investigation in clinical trial NCT02194465 (A Study of LY2623091 in Participants With High Blood Pressure).] |
|
PZM21
|
DB14030 |
[PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands such as morphine. [A33051]] |
|
LSZ-102
|
DB15362 |
[LSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).] |
|
Thallium Tl-201
|
DB15361 |
[Thallium Tl-201 is under investigation in clinical trial NCT02697760 (The CZT Dynamic Myocardial Perfusion Imaging).] |
|
Tretamine
|
DB14031 |
[Toxic alkylating agent used in industry; also as antineoplastic and research tool to produce chromosome aberrations and cancers.] |
|
Istiratumab
|
DB15363 |
[Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).] |
|
Acetyl sulfisoxazole
|
DB14033 |
[Sulfisoxazole acetyl is an ester of _sulfisoxazole_, a broad-spectrum sulfanilamide and a synthetic analog of para-aminobenzoic acid (PABA) with antibacterial activity. Sulfisoxazole acetyl competes with PABA for the bacterial enzyme, _dihydropteroate synthase_, preventing the incorporation of PABA into dihydrofolic acid, which is the precursor of folic acid. This process causes an inhibition of bacterial folic acid synthesis and de novo synthesis of purines and pyrimidines, resulting in cell growth arrest and cell death [L2788].
It is often combined with erythromycin to treat acute otitis media caused by the bacteria, haemophilus influenzae [L2790].] |
|
Carfentanil, C-11
|
DB15360 |
[Carfentanil, C-11 is under investigation in clinical trial NCT01899170 (Towards Individualized Deep Brain Stimulation Treatment of Chronic Neuropathic Pain).] |
|
Adenosine-5-Diphosphoribose
|
DB02059 |
|
|
Prostaglandin D2
|
DB02056 |
[The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.] |
|
3-[(2,4-Dichlorobenzoyl)(Isopropyl)Amino]-5-Phenylthiophene-2-Carboxylic Acid
|
DB03388 |
|
|
alpha-D-Xylopyranose
|
DB03389 |
|
|
N-Butyl-Benzenesulfonamide
|
DB02055 |
|
|
3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone
|
DB02058 |
|
|
4-Fluorotryptophane
|
DB03386 |
|
|
N-Hydroxy-N-Isopropyloxamic Acid
|
DB03387 |
|
|
(S)-AMPA
|
DB02057 |
[AMPA is a specific agonist for the AMPA receptor.] |
|
CRA_16847
|
DB02063 |
|
|
Enalkiren
|
DB03395 |
|
|
N-[3-[(1-Aminoethyl)(Hydroxy)Phosphoryl]-2-(1,1'-Biphenyl-4-Ylmethyl)Propanoyl]Alanine
|
DB02062 |
|
